ING Groep NV Has $22.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ING Groep NV grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 330.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,761 shares of the biopharmaceutical company's stock after acquiring an additional 16,701 shares during the quarter. ING Groep NV's holdings in Regeneron Pharmaceuticals were worth $22,876,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $25.70 on Friday, hitting $756.81. 1,374,476 shares of the company were exchanged, compared to its average volume of 530,457. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $83.17 billion, a P/E ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $753.69 and a 1-year high of $1,211.20. The firm has a 50 day moving average of $992.70 and a two-hundred day moving average of $1,033.92.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday. They set an "outperform" rating and a $1,150.00 target price on the stock. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Finally, Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,099.55.

Insider Activity

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.48% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.